Amyotropic Lateral Sclerosis (ALS) clinical trials at UCSF
7 in progress, 3 open to eligible people
ECoG BMI for Motor and Speech Control
open to eligible people ages 21 years and up
Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.
San Francisco, California
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
open to eligible people ages 18 years and up
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
San Francisco, California and other locations
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
open to eligible people ages 18 years and up
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.
San Francisco, California and other locations
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Sorry, in progress, not accepting new patients
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
San Francisco, California and other locations
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Sorry, in progress, not accepting new patients
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
San Francisco, California and other locations
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
Sorry, in progress, not accepting new patients
This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).
San Francisco, California and other locations
HEALEY ALS Platform Trial - Master Protocol
Sorry, not currently recruiting here
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
San Francisco, California and other locations
Our lead scientists for Amyotropic Lateral Sclerosis (ALS) research studies include Peter Ljubenkov Howie Rosen, MD Karunesh Ganguly, MD, PhD Adam Boxer, MD, PhD.
Last updated: